Fig. 1: Doxorubicin extends survival of WT leukemic mice but elicits long-term disease elimination in the absence of IL-6.

a A Kaplan–Meier survival curve showing leukemic WT mice, either treated with doxorubicin (DOX) or untreated. n = 11 for WT-untreated, n = 15 for WT-treated. ***p = 0.0001. b A Kaplan–Meier survival curve showing leukemic WT or immunodeficient Rag-2 KO mice, either treated with doxorubicin or untreated. n = 5 per cohort, except n = 4 for Rag-2 KO-untreated. c A Kaplan–Meier survival curve showing leukemic WT or IL-6 KO mice, either treated with doxorubicin or untreated. n = 16 for WT-untreated, n = 20 for WT-treated, n = 25 for IL-6 KO-untreated, n = 30 for IL-6 KO-treated. Data from 4 independent experiments are shown. ****p < 0.0001. d A graph showing leukemia burden in vivo monitored by bioluminescence imaging. Leukemia burden in WT and IL-6 KO mice at various times before and after treatment. n = 10 per cohort. *p = 0.0115 by two-tailed Mann–Whitney test. e Left: a graph showing the concentration of IL-6 present in the bone marrow of tumor-free or B-ALL-bearing mice. n = 8 per cohort. Right: a graph showing mCherry⁺ B-ALL percentages in the bone marrow of tumor-free or B-ALL bearing mice, quantified by flow cytometry. n = 10 for WT-ALL-untreated, n = 5 for WT-PBS-untreated, n = 6 for IL-6 KO-ALL-untreated. Data are represented as mean ± SEM. Shown are individual biological replicates. ***p = 0.0008, ****p < 0.0001 by Ordinary one-way ANOVA test. Log-rank (Mantel-Cox) tests were used to compare Kaplan–Meier survival curves. Boxplots show the median as the center lines, upper and lower quartiles as box limits, and whiskers represent maximum and minimum values. D2 = Day 2, D8 = Day 8. Source data are provided as a ‘Source data’ file.